



*For immediate release 7.00am: 30 December 2016*

**HVIVO PLC**  
("hVIVO" or the "Company")

**Change of auditor**

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that Ernst & Young LLP has been appointed by the Board of Directors with immediate effect as the Company's auditor and is replacing Deloitte LLP. The 2016 Annual Report for the year ending 31 December 2016 will be announced in April 2017. A resolution will be put before the shareholders at the Annual General Meeting to re-appoint Ernst & Young LLP as the Company's auditor.

**For further information please contact:**

**hVIVO plc**

+44 207 756 1300

Kym Denny (Chief Executive Officer)  
Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

**Numis Securities Limited**

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)  
James Black / Michael Burke (Corporate Broking)

**Notes to Editors:**

hVIVO plc ("hVIVO"), a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.